There is a significant need for new therapeutics to treat infections caused by the biodefense agent Bacillus anthracis. In pursuit of drug discovery against this organism, we have developed novel propargyl-linked inhibitors that target the essential enzyme dihydrofolate reductase (DHFR) from B. anthracis. Previously, we reported an initial series of these inhibitors and a high-resolution crystal structure of the ternary complex of the enzyme bound to its cofactor and one of the most potent inhibitors, UCP120B [Beierlein, J., Frey, K., Bolstad, D., Pelphrey, P., Joska, T., Smith, A., Priestley, N., Wright, D., and Anderson, A. (2008) J. Med. Chem. 51, 7532-7540]. Herein, we describe a threedimensional solution structure of the ternary complex as determined by NMR. A comparison of this solution structure to the crystal structure reveals a general conservation of the DHFR fold and cofactor interactions as well as differences in the location of an active site helix and specific ligand interactions. In addition to data for the fully assigned ternary complex, data for the binary (enzymecofactor) complex were collected, providing chemical shift comparisons and revealing perturbations in residues that accommodate ligand binding. Dynamics of the protein, measured using 15 N T 1 and T 2 relaxation times and { 1 H}-15 N heteronuclear NOEs, reveal residue flexibility at the active site that explains enzyme inhibition and structure-activity relationships for two different series of these propargyl-linked inhibitors. The information obtained from the solution structure regarding active site flexibility will be especially valuable in the design of inhibitors with increased potency.Bacillus anthracis, the causative agent of anthrax, is a well-known bioterrorism threat. The limited number of approved therapeutics exhibit serious drawbacks including indication spectrum, resistance, and expense, especially in a case of large-scale exposure. The development of stable, effective new therapeutics is certainly warranted.Dihydrofolate reductase (DHFR), 1 an essential enzyme in cellular metabolism, catalyzes the reduction of di-hydrofolate to form tetrahydrofolate using the cofactor NADPH. Over the past five decades, DHFR has been recognized as a validated drug target for both human ‡ Coordinates have been deposited in the Protein Data Bank with accession code 2KGK. † Funding provided by NIH Grant R01AI073375 (to A.C.A.). Figure S1 showing a superposition of the binary and ternary LcDHFR structures with structural differences noted and tables of chemical shift assignments for NADPH (Table S1) and UCP120B (Table S2) as well as a table of NOE signals involving helix B and the ligand (Table S3). This material is available free of charge via the Internet at http://pubs.acs.org. In general, the solution structures are similar to the related X-ray crystal structures and yield additional details regarding the cooperativity of cofactor and ligand binding. Specifically, the solution structures of LcDHFR and hDHFR bound to NADPH and tri...